Germline mutations in its interacting partner BRCA2 are known to predispose to cancers of the breast, ovary and pancreas, as well as confer a moderate increased risk of CMM (relative risk of 2.6 [2], [3]), suggesting by association that PALB2 may also play a role in tumour development in these cancer types. This evidence concerns the gene PALB2 and neoplasm.